Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2026
Selenium and zinc in acute kidney injury: A systematic scoping review of speciation-resolved mechanisms, analytical validation, and translational biomarkers.
СтатьяScoping ReviewНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Visht Sharad, Abbas Muhamed Aydin, Porwal Omji, Muhammed Rozhan Arif, Fuloria Neeraj Kumar, Othman Zainab Yalman, Shaban Sama Naziyah, Kumar Bimlesh, Dudhe Rupesh, Singh Sachin Kumar
Аннотация
PURPOSE: To assess selenium (Se) and zinc (Zn) Status, mechanisms, analytical methods and biomarker potential in acute kidney injury (AKI).
METHODS: The search was conducted in PubMed, Embase, Web of Science, and Scopus databases, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) up to February 2026. Only primary experimental, clinical and analytical studies that reported quantitative data for Se or Zn in AKI were included. Design-specific tools were used for methodological quality and risk of bias assessment.
RESULTS: Low plasma Se (<70 µg/L; <0.89 µmol/L) and Zn (<60 µg/dL; <9.2 µmol/L) was associated with increased incidence, severity, and mortality of AKI in clinical cohorts (n = 453-11,238); however, these relationships may be confounded by inflammation, acute-phase redistribution, and disease severity. Although preclinical evidence points to a role for glutathione peroxidase 4 (GPX4)-regulated ferroptosis, and for the zinc importer/zinc exporter (ZIP/ZnT)-nuclear factor kappa B (NF-κB)-NOD-, leucine-rich repeat- and pyrin domain-containing protein 3 (NLRP3) signalling, these have not yet been validated in humans.
CONCLUSION: Selenoprotein P (SELENOP), glutathione peroxidase 3 (GPX3) and urinary Zn(II) and metallothionein (MT) constitute a proposed panel for clinical implementation, which needs to be analytically validated, discriminated and calibrated, externally validated, incrementally valued and clinically utility evaluated in prospective multicentre studies.
METHODS: The search was conducted in PubMed, Embase, Web of Science, and Scopus databases, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) up to February 2026. Only primary experimental, clinical and analytical studies that reported quantitative data for Se or Zn in AKI were included. Design-specific tools were used for methodological quality and risk of bias assessment.
RESULTS: Low plasma Se (<70 µg/L; <0.89 µmol/L) and Zn (<60 µg/dL; <9.2 µmol/L) was associated with increased incidence, severity, and mortality of AKI in clinical cohorts (n = 453-11,238); however, these relationships may be confounded by inflammation, acute-phase redistribution, and disease severity. Although preclinical evidence points to a role for glutathione peroxidase 4 (GPX4)-regulated ferroptosis, and for the zinc importer/zinc exporter (ZIP/ZnT)-nuclear factor kappa B (NF-κB)-NOD-, leucine-rich repeat- and pyrin domain-containing protein 3 (NLRP3) signalling, these have not yet been validated in humans.
CONCLUSION: Selenoprotein P (SELENOP), glutathione peroxidase 3 (GPX3) and urinary Zn(II) and metallothionein (MT) constitute a proposed panel for clinical implementation, which needs to be analytically validated, discriminated and calibrated, externally validated, incrementally valued and clinically utility evaluated in prospective multicentre studies.